Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Aug 4;10(10):1939–1948. doi: 10.1158/1535-7163.MCT-11-0228

Table 1c. Additional Confirmation of Candidates.

To test the MUC16 selectivity of the nominated compounds following the A2780 isogenic screens additional matched, isogenic MUC16 positive/negative pairs were examined. The IC50’s, obtained graphically following 96 well plate Alamar Blue assays are shown. While 3 of 4 compounds were confirmed as more selective for MUC16 expressing cells in the SKOV3 pair, 4 of four were confirmed in the T80 paired cell lines and 3 of 4 (except Quinacrine) were more toxic for the MUC16 expressing SKOv8 cells than for the stable siRNA MUC16 knockdowns which show less than 10% of the parental levels of MUC16.

Compounds SKOV3 T80 SKOV8 CAOV3 OVCAR3
No MUC16 MUC16+ve No MUC16 MUC16 +ve No MUC16 MUC16 +ve MUC16 +ve MUC16 +ve
Knock Down Scramble WT WT
Ellipticine 4.5 4 0.3 0.25 0.2 0.11 0.6 0.7
Quinacrine dihydrochloride dihydrate 4.125 3.5 4.5 3.5 0.5 1.1 8 7
Acriflavinium hydrochloride 4.25 5.5 1.8 1.4 0.5 0.25 0.7 1
Rutilantinone 50 47.5 10.8 9.5 19 15 9 10